Stockscreener 앱 받기
0.4041
1.02%
0.0041
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
ENSC Ensysce Biosciences reports narrower Q4 2025 loss than estimates, shares climb after earnings release.Barrier to Entry - Newser
ENSC Should I Buy - Intellectia AI
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences (ENSC) Sector Trends | Q4 2025: EPS Beats ForecastsCommunity Chart Signals - UBND thành phố Hải Phòng
Ensysce Biosciences : Corporate Overview - marketscreener.com
Ensysce receives IRB approval for final opioid overdose study phase By Investing.com - Investing.com India
Ensysce Biosciences Secures IRB Approval for Final Phase of Clinical Study - National Today
Ensysce receives IRB approval for final opioid overdose study phase - Investing.com
Opioid with built-in overdose safeguard enters final study stage - Stock Titan
[EFFECT] Ensysce Biosciences, Inc. SEC Filing - Stock Titan
Price Action: Will Ensysce Biosciences Inc benefit from geopolitical trendsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Bull Run: Is Ensysce Biosciences Inc subject to activist investor interest2026 Dividend Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
What is the volatility of Ensysce Biosciences (ENSC) Stock | Price at $0.48, Up 0.21%Growth Investing - Newser
Ensysce Biosciences (NASDAQ: ENSC) registers 20.3M resale shares - Stock Titan
Ensysce Biosciences Secures $2 Million Second Tranche Financing to Advance Abuse-Resistant Pain Therapies - Minichart
Ensysce Biosciences Secures $2 Million Private Financing - TipRanks
Ensysce Biosciences (NASDAQ: ENSC) closes $2M preferred and warrant deal - Stock Titan
Ensysce Raises $2 Million in Private Placement of Series B Preferred and Warrants - TradingView
Can Ensysce Biosciences (ENSC) Stock Beat Estimates | Price at $0.55, Down 4.96%Real Trader Network - Newser
Ensysce Biosciences closes $2M convertible preferred financing By Investing.com - Investing.com South Africa
Ensysce Biosciences Secures Second Financing to Advance Pain Programs - National Today
Ensysce Biosciences closes $2M convertible preferred financing - Investing.com
Pain drug developer pulls another $2M for overdose-resistant treatments - Stock Titan
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - The Globe and Mail
Aug Swings: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Stop Loss: Whats the RSI of PETWW stock2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
Is Ensysce Biosciences (ENSC) Stock in a Selling Zone | Price at $0.58, Down 5.12%Price Target - Newser
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board By Investing.com - Investing.com India
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - Stock Titan
ENSC Stock Analysis: Ensysce Biosciences Inc biotech gains 11.52 percent to 0.61 dollars - UBND thành phố Hải Phòng
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Gains Ground as Investors Pile In - Newser
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Moomoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView — Track All Markets
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - Stock Titan
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - Stock Titan
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
0.78%
3.01%
자본화:
|
볼륨(24시간):